<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="pds70162" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacoepidemiol Drug Saf</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-1557</journal-id><journal-id journal-id-type="publisher-id">PDS</journal-id><journal-title-group><journal-title>Pharmacoepidemiology and Drug Safety</journal-title></journal-title-group><issn pub-type="ppub">1053-8569</issn><issn pub-type="epub">1099-1557</issn><publisher><publisher-name>John Wiley &#x00026; Sons, Inc.</publisher-name><publisher-loc>Chichester, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12094858</article-id><article-id pub-id-type="doi">10.1002/pds.70162</article-id><article-id pub-id-type="publisher-id">PDS70162</article-id><article-id pub-id-type="other">PDS-25-0124.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Association Between Ceftriaxone Use and Biliary Infections in Patients With Pneumonia: A Nationwide Retrospective Cohort Study</article-title></title-group><contrib-group><contrib id="pds70162-cr-0001" contrib-type="author" corresp="yes"><name><surname>Taniguchi</surname><given-names>Jumpei</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2480-9018</contrib-id><xref rid="pds70162-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>taniguchi-jumpei0825@g.ecc.u-tokyo.ac.jp</email></address></contrib><contrib id="pds70162-cr-0002" contrib-type="author"><name><surname>Aso</surname><given-names>Shotaro</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7804-2433</contrib-id><xref rid="pds70162-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="pds70162-cr-0003" contrib-type="author"><name><surname>Matsui</surname><given-names>Hiroki</given-names></name><xref rid="pds70162-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="pds70162-cr-0004" contrib-type="author"><name><surname>Fushimi</surname><given-names>Kiyohide</given-names></name><xref rid="pds70162-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="pds70162-cr-0005" contrib-type="author"><name><surname>Yasunaga</surname><given-names>Hideo</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6017-469X</contrib-id><xref rid="pds70162-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="pds70162-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Epidemiology and Health Economics, School of Public Health</named-content>
<institution>The University of Tokyo</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="pds70162-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Health Services Research, Graduate School of Medicine</named-content>
<institution>The University of Tokyo</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><aff id="pds70162-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences</named-content>
<institution>Institute of Science Tokyo</institution>
<city>Tokyo</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Jumpei Taniguchi (<email>taniguchi-jumpei0825@g.ecc.u-tokyo.ac.jp</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>34</volume><issue seq="50">6</issue><issue-id pub-id-type="doi">10.1002/pds.v34.6</issue-id><elocation-id>e70162</elocation-id><history>
<date date-type="rev-recd"><day>10</day><month>5</month><year>2025</year></date>
<date date-type="received"><day>22</day><month>2</month><year>2025</year></date>
<date date-type="accepted"><day>12</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons, Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Pharmacoepidemiology and Drug Safety</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PDS-34-e70162.pdf"/><abstract><title>ABSTRACT</title><sec id="pds70162-sec-0001"><title>Background</title><p>Ceftriaxone is believed to increase the risk of biliary infections due to pseudolithiasis caused by ceftriaxone&#x02010;calcium precipitation, but this risk is not well understood. This study aimed to investigate whether ceftriaxone use is associated with an increased risk of biliary infections in pneumonia patients using a national inpatient database.</p></sec><sec id="pds70162-sec-0002"><title>Methods</title><p>We analyzed the Diagnosis Procedure Combination database in Japan, identifying pneumonia patients between July 2010 and March 2022. Patients were grouped by treatment: ceftriaxone versus ampicillin&#x02010;sulbactam or cefotaxime. Propensity score overlap&#x02010;weighting was used to adjust for confounding factors. The primary outcome was a composite measure, including cholecystitis or cholangitis during hospitalization, and any percutaneous, endoscopic, or surgical interventions on the biliary tract. Secondary outcomes included individual components of the primary outcome.</p></sec><sec id="pds70162-sec-0003"><title>Results</title><p>Of the 1&#x02009;503&#x02009;885 eligible patients, 558&#x02009;725 received ceftriaxone, while 945&#x02009;160 were treated with either ampicillin&#x02010;sulbactam or cefotaxime. The mean dose of ceftriaxone was 1.7&#x02009;g/day (standard deviation, 0.7&#x02009;g/day), with a mean administration duration of 7.1&#x02009;days (standard deviation, 3.8&#x02009;days). Propensity score overlap&#x02010;weighting analysis revealed that ceftriaxone treatment was associated with an increased incidence of the composite outcome (0.22% vs. 0.18%; risk difference, 0.05%; 95% confidence interval, 0.03%&#x02013;0.07%; <italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.001), as well as the secondary outcomes, including cholecystitis or cholangitis during hospitalization and percutaneous or endoscopic drainage of the gallbladder or biliary tract.</p></sec><sec id="pds70162-sec-0004"><title>Conclusion</title><p>Ceftriaxone use was associated with a slight increase in the risk of biliary infections.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="pds70162-kwd-0001">biliary infection</kwd><kwd id="pds70162-kwd-0002">ceftriaxone</kwd><kwd id="pds70162-kwd-0003">cholangitis</kwd><kwd id="pds70162-kwd-0004">cholecystitis</kwd><kwd id="pds70162-kwd-0005">pseudolithiasis</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>The Ministry of Health, Labor and Welfare, Japan</funding-source><award-id>23AA2003</award-id><award-id>24AA2006</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="9"/><word-count count="5100"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="pds70162-ntgp-0001"><fn fn-type="funding" id="pds70162-note-0001"><p>
<bold>Funding:</bold> This work was supported by grants from the Ministry of Health, Labor and Welfare, Japan (23AA2003 and 24AA2006).</p></fn></fn-group></notes></front><body id="pds70162-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="pds70162-blkfxd-0001"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="pds70162-list-0001"><list-item id="pds70162-li-0001"><p>Ceftriaxone use was associated with a slight but statistically significant increase in the incidence of biliary infections, including cholecystitis and cholangitis, compared with ampicillin&#x02010;sulbactam and cefotaxime.</p></list-item><list-item id="pds70162-li-0002"><p>These results remained consistent across sensitivity analyses using other comparisons.</p></list-item><list-item id="pds70162-li-0003"><p>Clinicians should be aware of the potential risk.</p></list-item></list>
</p></boxed-text>
</p><sec><def-list list-content="abbreviations" id="pds70162-dl-0001"><title>Abbreviation</title><def-item><term id="pds70162-li-0004">ICD&#x02010;10</term><def id="pds70162-li-0005"><p>International Classification of Diseases 10th revision</p></def></def-item></def-list></sec><sec id="pds70162-sec-0008"><label>1</label><title>Introduction</title><p>Ceftriaxone is a third&#x02010;generation cephalosporin with a broad antimicrobial spectrum [<xref rid="pds70162-bib-0001" ref-type="bibr">1</xref>]. It is commonly used for treating a variety of bacterial infections, including pneumonia [<xref rid="pds70162-bib-0002" ref-type="bibr">2</xref>]. Ceftriaxone is excreted in bile, where it accumulates at concentrations 20&#x02013;150 times higher than that in serum [<xref rid="pds70162-bib-0003" ref-type="bibr">3</xref>]. It binds to calcium ions in bile, inducing reversible precipitation and crystallization [<xref rid="pds70162-bib-0004" ref-type="bibr">4</xref>].</p><p>These ceftriaxone&#x02010;calcium precipitates had been well studied in pediatric patients [<xref rid="pds70162-bib-0005" ref-type="bibr">5</xref>, <xref rid="pds70162-bib-0006" ref-type="bibr">6</xref>, <xref rid="pds70162-bib-0007" ref-type="bibr">7</xref>]. However, recent studies have suggested that pseudolithiasis due to ceftriaxone&#x02010;calcium precipitation could also occur in approximately 10%&#x02013;20% of adult patients [<xref rid="pds70162-bib-0004" ref-type="bibr">4</xref>, <xref rid="pds70162-bib-0008" ref-type="bibr">8</xref>, <xref rid="pds70162-bib-0009" ref-type="bibr">9</xref>, <xref rid="pds70162-bib-0010" ref-type="bibr">10</xref>]. Pseudolithiasis can occasionally lead to biliary infections, such as cholecystitis or cholangitis, which pose a significant clinical concern; however, to what extent ceftriaxone could contribute to the risk of such infections remains unclear [<xref rid="pds70162-bib-0011" ref-type="bibr">11</xref>, <xref rid="pds70162-bib-0012" ref-type="bibr">12</xref>, <xref rid="pds70162-bib-0013" ref-type="bibr">13</xref>, <xref rid="pds70162-bib-0014" ref-type="bibr">14</xref>, <xref rid="pds70162-bib-0015" ref-type="bibr">15</xref>].</p><p>Therefore, this study aims to investigate whether the use of ceftriaxone is associated with an increased risk of cholecystitis and cholangitis in adult patients with pneumonia, using a nationwide inpatient database.</p></sec><sec sec-type="methods" id="pds70162-sec-0009"><label>2</label><title>Methods</title><sec id="pds70162-sec-0010"><label>2.1</label><title>Study Design and Setting</title><p>This retrospective cohort study utilized the Japanese Diagnosis Procedure Combination inpatient database, which includes comprehensive data from over 1200 hospitals across Japan.</p></sec><sec id="pds70162-sec-0011"><label>2.2</label><title>Patient Data</title><p>We identified patients diagnosed with pneumonia (International Classification of Diseases, 10th Revision [ICD&#x02010;10] codes: J10.x&#x02013;J18.x, J69.x) between July 2010 and March 2022 from the database. If a patient was hospitalized more than once for pneumonia during the study period, only the first hospitalization was included. We included patients who received ceftriaxone, ampicillin&#x02010;sulbactam, or cefotaxime within 2&#x02009;days of admission. We excluded patients who were treated with ceftriaxone, and ampicillin&#x02010;sulbactam or cefotaxime, at the same time; patients with disease of gallbladder (ICD&#x02010;10 codes: K56.3, K80.x, K81.x, K82.x, K85.1); patients with diseases of biliary tract (ICD&#x02010;10 codes: K74.3, K83.x, K91.8); patients with malignant neoplasm of gallbladder or biliary tract (ICD&#x02010;10 codes: C22.1, C23.x, C24.x, D13.4, D13.5, D37.6); patients with medical history of cholecystectomy (ICD&#x02010;10 codes: K91.5, Z90.4); patients treated with ursodiol within 2&#x02009;days of admission; patients aged &#x0003c;&#x02009;15&#x02009;years; and pregnant patients.</p></sec><sec id="pds70162-sec-0012"><label>2.3</label><title>Data Source</title><p>We utilized the Japanese Diagnosis Procedure Combination inpatient database containing comprehensive data on patient demographics (age, sex, height, and weight), primary diagnosis, comorbidities at admission, complications arising during hospitalization (coded according to the ICD&#x02010;10), dates of admission and discharge, prescribed medications, procedures, surgeries, and hospital identification numbers [<xref rid="pds70162-bib-0016" ref-type="bibr">16</xref>]. This database holds detailed administrative and discharge records from over 1200 hospitals across Japan [<xref rid="pds70162-bib-0017" ref-type="bibr">17</xref>].</p></sec><sec id="pds70162-sec-0013"><label>2.4</label><title>Exposure</title><p>Patients were divided into two groups: those who received ceftriaxone (the ceftriaxone group) and those who received ampicillin&#x02010;sulbactam or cefotaxime (the control group) within 2&#x02009;days of admission. The antimicrobial spectra of ampicillin&#x02010;sulbactam and cefotaxime are similar to that of ceftriaxone; both are widely used for the treatment of community&#x02010;acquired pneumonia. Ceftriaxone is known to be excreted into the gallbladder, potentially leading to the formation of ceftriaxone&#x02010;calcium precipitates, while ampicillin&#x02010;sulbactam and cefotaxime are primarily excreted by the kidneys, without reports of inducing calcium precipitate formation. Therefore, ampicillin&#x02010;sulbactam and cefotaxime were selected as comparators.</p></sec><sec id="pds70162-sec-0014"><label>2.5</label><title>Covariates and Outcomes</title><p>Covariates were classified into three categories: baseline patient characteristics, treatments received within 2&#x02009;days of admission, and hospital characteristics. Baseline patient characteristics included factors such as age, sex, body mass index at admission, smoking status (nonsmoker, current or former smoker), Glasgow Coma Scale score at admission, Barthel Index [<xref rid="pds70162-bib-0018" ref-type="bibr">18</xref>], whether the patient was admitted to an intensive care unit or high care unit, and comorbidities (including lung diseases [chronic obstructive pulmonary disease, interstitial pneumonia, bronchiectasis or non&#x02010;tuberculosis mycobacterium of lungs, fungal lung disease, lung tumors, chronic respiratory failure], cardiovascular disease, chronic kidney disease, liver disease, diabetes mellitus, dyslipidemia, non&#x02010;hematological malignancies, hematological malignancies, and dementia) (Table&#x000a0;<xref rid="pds70162-supitem-0001" ref-type="supplementary-material">S1</xref>). Treatments received within the 2&#x02009;days of admission included oxygen therapy, mechanical ventilation, the use of vasopressors, renal replacement therapy, oral feeding, nasogastric feeding, total parenteral nutrition, medications associated with gallstone formation (e.g., fibrates, somatostatin analogs, and hormone replacement), antibiotics (e.g., macrolides, fluoroquinolones, doxycycline, and anti&#x02010;methicillin&#x02010;resistant <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Staphylococcus aureus</italic>
</styled-content>), and steroids. Hospital characteristics included whether the patient was admitted to a teaching hospital.</p><p>Body mass index was categorized into the following groups: &#x0003c;&#x02009;18.5, 18.5&#x02013;24.9, 25.0&#x02013;29.9, and &#x02265;&#x02009;30.0&#x02009;kg/m<sup>2</sup>. The Japan Coma Scale score was converted to the Glasgow Coma Scale score based on a prior study [<xref rid="pds70162-bib-0019" ref-type="bibr">19</xref>], as the two scales have been shown to be well&#x02010;correlated [<xref rid="pds70162-bib-0020" ref-type="bibr">20</xref>]. The Barthel Index was categorized into four groups: 0, 5&#x02013;50, 55&#x02013;95, and 100. Steroid use was defined as the administration of at least 200&#x02009;mg/day of hydrocortisone or an equivalent dose of another corticosteroid.</p><p>The primary outcome was defined as a composite of the following: cholecystitis or cholangitis (ICD&#x02010;10 codes: K80.0, K80.1, K80.3, K80.4, K81.x, K83.0), percutaneous or endoscopic drainage of the gallbladder or biliary tract, and surgical interventions on the gallbladder or biliary tract during hospitalization. Secondary outcomes were defined as each individual component of the primary outcome.</p></sec><sec id="pds70162-sec-0015"><label>2.6</label><title>Statistical Analyses</title><p>We applied a propensity&#x02010;score overlap&#x02010;weighting method to compare the outcomes between the two groups [<xref rid="pds70162-bib-0021" ref-type="bibr">21</xref>, <xref rid="pds70162-bib-0022" ref-type="bibr">22</xref>]. Propensity scores were derived from a logistic regression model, with the dependent variable being ceftriaxone use and all covariates included as independent variables. Overlap weighting involves assigning weights to patients based on their likelihood of receiving the opposing treatment [<xref rid="pds70162-bib-0022" ref-type="bibr">22</xref>]. In this study, patients treated with ceftriaxone were weighted by the probability of not receiving ceftriaxone (1&#x02009;&#x02212;&#x02009;propensity score), while those who did not receive ceftriaxone were weighted by their probability of receiving ceftriaxone (propensity score). This overlap&#x02010;weighting approach helps balance covariates between groups, mimicking the conditions of a randomized trial without excluding any patients from the analysis. Standardized differences for each covariate were computed, with absolute standardized differences less than 10% indicating adequate balance [<xref rid="pds70162-bib-0023" ref-type="bibr">23</xref>, <xref rid="pds70162-bib-0024" ref-type="bibr">24</xref>].</p><p>For statistical analysis, continuous variables were evaluated using <italic toggle="yes">t</italic>&#x02010;tests and are expressed as means with standard deviations. Categorical variables were analyzed using the chi&#x02010;square test and are presented as frequencies and percentages. A two&#x02010;sided <italic toggle="yes">p</italic>&#x02010;value of &#x0003c;&#x02009;0.05 was considered statistically significant. All analyses were conducted using STATA/SE version 18.0 (StataCorp, College Station, TX, USA).</p></sec><sec id="pds70162-sec-0016"><label>2.7</label><title>Sensitivity Analysis</title><p>We conducted several sensitivity analyses. First, we restricted the analysis to patients receiving a high dose of ceftriaxone (&#x02265;&#x02009;2&#x02009;g/day) in the ceftriaxone group [<xref rid="pds70162-bib-0025" ref-type="bibr">25</xref>]. Second, we compared the outcomes between ceftriaxone and piperacillin&#x02010;tazobactam as an alternative control. Third, we restricted the control group to patients who received cefotaxime, which has an antibacterial spectrum similar to ceftriaxone but is primarily excreted renally. Fourth, we performed an additional analysis that included patients who were readmitted for biliary infections within 30&#x02009;days after discharge to account for the possibility that outcomes might have occurred after discharge.</p></sec><sec id="pds70162-sec-0017"><label>2.8</label><title>Ethics</title><p>This study received ethical approval from the Institutional Review Board of the University of Tokyo (3501&#x02010;(5), May 19th, 2021). Written informed consent was waived due to the retrospective design and use of anonymized data.</p></sec></sec><sec sec-type="results" id="pds70162-sec-0018"><label>3</label><title>Results</title><p>We identified 1&#x02009;787&#x02009;095 patients who were hospitalized for pneumonia and received antibiotics, including ampicillin&#x02010;sulbactam, cefotaxime, or ceftriaxone, between July 2010 and March 2022 (Figure&#x000a0;<xref rid="pds70162-fig-0001" ref-type="fig">1</xref>). Of these, 1&#x02009;503&#x02009;885 patients were eligible for inclusion in the analysis, with 558&#x02009;725 and 945&#x02009;160 patients in the ceftriaxone and control groups, respectively. In the ceftriaxone group, the mean initial dose of ceftriaxone was 1.7&#x02009;g/day (standard deviation, 0.7&#x02009;g/day); the mean duration of administration was 7.1&#x02009;days (standard deviation, 3.8&#x02009;days). In the control group, the mean duration of administration was 7.7&#x02009;days (standard deviation, 4.1&#x02009;days). The mean length of hospital stay was 20 (standard deviation, 30&#x02009;days) and 23 (standard deviation, 31&#x02009;days) days in the ceftriaxone and control groups, respectively.</p><fig position="float" fig-type="FIGURE" id="pds70162-fig-0001"><label>FIGURE 1</label><caption><p>Study design. This flowchart illustrates the inclusion and exclusion criteria for the study. A total of 1&#x02009;787&#x02009;095 patients who underwent their first hospitalization for pneumonia and received antibiotics (ceftriaxone, ampicillin&#x02010;sulbactam, or cefotaxime) within 2&#x02009;days of admission between July 2010 and March 2022 were screened. After excluding 283&#x02009;210 patients based on criteria such as concurrent antibiotic treatment, gallbladder or biliary tract disease, malignancies, use of ursodiol, previous cholecystectomy, age&#x02009;&#x0003c;&#x02009;15&#x02009;years, and pregnancy, 1&#x02009;503&#x02009;885 patients were eligible for the study. Eligible patients were divided into two groups: Ceftriaxone group (<italic toggle="yes">N</italic>&#x02009;=&#x02009;558&#x02009;725) and control group (<italic toggle="yes">N</italic>&#x02009;=&#x02009;945&#x02009;160).</p></caption><graphic xlink:href="PDS-34-e70162-g001" position="anchor" id="jats-graphic-1"/></fig><p>Table&#x000a0;<xref rid="pds70162-tbl-0001" ref-type="table">1</xref> shows the baseline characteristics of the study groups before and after propensity&#x02010;score overlap weighting. Compared with the control group, patients in the ceftriaxone group were younger, had a higher BMI, had less altered consciousness, had better Barthel Index scores, were more likely to have chronic kidney failure, and were more likely to receive oral feeding and macrolide treatment within 2&#x02009;days of admission. In the unweighted population, there were no significant differences in the proportions of the composite outcome between the ceftriaxone and control groups (0.21% [1181/558&#x02009;725] vs. 0.20% [1903/945&#x02009;160]; risk difference [RD], 0.01%; 95% confidence interval [CI], &#x02212;0.00% to 0.03%; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.189).</p><table-wrap position="float" id="pds70162-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Variables</th><th align="center" colspan="3" valign="bottom" rowspan="1">Unweighted population</th><th align="center" colspan="3" valign="bottom" rowspan="1">Propensity&#x02010;score overlap weighted population</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Control (<italic toggle="yes">n</italic>&#x02009;=&#x02009;945&#x02009;160)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ceftriaxone (<italic toggle="yes">n</italic>&#x02009;=&#x02009;558&#x02009;725)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Standardized difference</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ceftriaxone</th><th align="center" valign="bottom" rowspan="1" colspan="1">Standardized difference</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">79.9 (13.6)</td><td align="center" valign="top" rowspan="1" colspan="1">77.4 (15.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;17.6</td><td align="center" valign="top" rowspan="1" colspan="1">77.6 (15.2)</td><td align="center" valign="top" rowspan="1" colspan="1">77.6 (15.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">533&#x02009;288 (56.4)</td><td align="center" valign="top" rowspan="1" colspan="1">315&#x02009;800 (56.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.2</td><td align="center" valign="top" rowspan="1" colspan="1">(55.7)</td><td align="center" valign="top" rowspan="1" colspan="1">(55.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">BMI, kg/m<sup>2</sup>, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;18.50</td><td align="center" valign="top" rowspan="1" colspan="1">298&#x02009;426 (31.6)</td><td align="center" valign="top" rowspan="1" colspan="1">146&#x02009;992 (26.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;11.6</td><td align="center" valign="top" rowspan="1" colspan="1">(32.3)</td><td align="center" valign="top" rowspan="1" colspan="1">(32.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">18.50&#x02013;24.99</td><td align="center" valign="top" rowspan="1" colspan="1">416&#x02009;181 (44.0)</td><td align="center" valign="top" rowspan="1" colspan="1">269&#x02009;418 (48.2)</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td><td align="center" valign="top" rowspan="1" colspan="1">(54.1)</td><td align="center" valign="top" rowspan="1" colspan="1">(54.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">25.00&#x02013;29.99</td><td align="center" valign="top" rowspan="1" colspan="1">75&#x02009;948 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">59&#x02009;912 (10.7)</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td><td align="center" valign="top" rowspan="1" colspan="1">(11.1)</td><td align="center" valign="top" rowspan="1" colspan="1">(11.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;30.00</td><td align="center" valign="top" rowspan="1" colspan="1">14&#x02009;972 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">13&#x02009;955 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">6.5</td><td align="center" valign="top" rowspan="1" colspan="1">(2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">(2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing data</td><td align="center" valign="top" rowspan="1" colspan="1">139&#x02009;633 (14.8)</td><td align="center" valign="top" rowspan="1" colspan="1">68&#x02009;448 (12.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.4</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Smoking history, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Patient who does not smoke</td><td align="center" valign="top" rowspan="1" colspan="1">585&#x02009;929 (62.0)</td><td align="center" valign="top" rowspan="1" colspan="1">334&#x02009;100 (59.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;4.5</td><td align="center" valign="top" rowspan="1" colspan="1">(68.5)</td><td align="center" valign="top" rowspan="1" colspan="1">(68.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Patient who currently smokes/patient who previously smoked</td><td align="center" valign="top" rowspan="1" colspan="1">230&#x02009;682 (24.4)</td><td align="center" valign="top" rowspan="1" colspan="1">155&#x02009;989 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">8.0</td><td align="center" valign="top" rowspan="1" colspan="1">(31.5)</td><td align="center" valign="top" rowspan="1" colspan="1">(31.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing data</td><td align="center" valign="top" rowspan="1" colspan="1">128&#x02009;549 (13.6)</td><td align="center" valign="top" rowspan="1" colspan="1">68&#x02009;636 (12.3)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.9</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GCS on admission, mean (SD)</td><td align="center" valign="top" rowspan="1" colspan="1">14.1 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">14.4 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">16.6</td><td align="center" valign="top" rowspan="1" colspan="1">14.4 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">14.4 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Barthel index on admission, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">345&#x02009;195 (36.5)</td><td align="center" valign="top" rowspan="1" colspan="1">142&#x02009;788 (25.6)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;23.9</td><td align="center" valign="top" rowspan="1" colspan="1">(31.5)</td><td align="center" valign="top" rowspan="1" colspan="1">(31.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">5&#x02013;50</td><td align="center" valign="top" rowspan="1" colspan="1">186&#x02009;228 (19.7)</td><td align="center" valign="top" rowspan="1" colspan="1">108&#x02009;475 (19.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.7</td><td align="center" valign="top" rowspan="1" colspan="1">(22.8)</td><td align="center" valign="top" rowspan="1" colspan="1">(22.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">55&#x02013;95</td><td align="center" valign="top" rowspan="1" colspan="1">99&#x02009;369 (10.5)</td><td align="center" valign="top" rowspan="1" colspan="1">77&#x02009;586 (13.9)</td><td align="center" valign="top" rowspan="1" colspan="1">10.3</td><td align="center" valign="top" rowspan="1" colspan="1">(15.6)</td><td align="center" valign="top" rowspan="1" colspan="1">(15.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="top" rowspan="1" colspan="1">180&#x02009;351 (19.1)</td><td align="center" valign="top" rowspan="1" colspan="1">153&#x02009;925 (27.5)</td><td align="center" valign="top" rowspan="1" colspan="1">20.1</td><td align="center" valign="top" rowspan="1" colspan="1">(30.1)</td><td align="center" valign="top" rowspan="1" colspan="1">(30.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Missing data</td><td align="center" valign="top" rowspan="1" colspan="1">134&#x02009;017 (14.2)</td><td align="center" valign="top" rowspan="1" colspan="1">75&#x02009;951 (13.6)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.7</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ICU or HCU admission, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">36&#x02009;116 (3.8)</td><td align="center" valign="top" rowspan="1" colspan="1">17&#x02009;968 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.3</td><td align="center" valign="top" rowspan="1" colspan="1">(3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">(3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Lung disease, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic obstructive pulmonary disease</td><td align="center" valign="top" rowspan="1" colspan="1">67&#x02009;272 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">48&#x02009;235 (8.6)</td><td align="center" valign="top" rowspan="1" colspan="1">5.6</td><td align="center" valign="top" rowspan="1" colspan="1">(8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">(8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Interstitial Pneumonia</td><td align="center" valign="top" rowspan="1" colspan="1">21&#x02009;205 (2.2)</td><td align="center" valign="top" rowspan="1" colspan="1">16&#x02009;693 (3.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td><td align="center" valign="top" rowspan="1" colspan="1">(2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">(2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Bronchiectasis &#x00026; NTM of the lungs</td><td align="center" valign="top" rowspan="1" colspan="1">10&#x02009;065 (1.1)</td><td align="center" valign="top" rowspan="1" colspan="1">7107 (1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1.9</td><td align="center" valign="top" rowspan="1" colspan="1">(1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">(1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Fungal lung disease</td><td align="center" valign="top" rowspan="1" colspan="1">2456 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">1585 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td><td align="center" valign="top" rowspan="1" colspan="1">(0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">(0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Lung tumors</td><td align="center" valign="top" rowspan="1" colspan="1">31&#x02009;806 (3.4)</td><td align="center" valign="top" rowspan="1" colspan="1">17&#x02009;294 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.4</td><td align="center" valign="top" rowspan="1" colspan="1">(3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">(3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Chronic respiratory failure</td><td align="center" valign="top" rowspan="1" colspan="1">18&#x02009;344 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">11&#x02009;608 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1">(2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">(2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiovascular disease, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">161&#x02009;652 (17.1)</td><td align="center" valign="top" rowspan="1" colspan="1">106&#x02009;155 (19.0)</td><td align="center" valign="top" rowspan="1" colspan="1">4.9</td><td align="center" valign="top" rowspan="1" colspan="1">(18.2)</td><td align="center" valign="top" rowspan="1" colspan="1">(18.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney failure, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">38&#x02009;100 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">42&#x02009;011 (7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">14.9</td><td align="center" valign="top" rowspan="1" colspan="1">(5.7)</td><td align="center" valign="top" rowspan="1" colspan="1">(5.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver disease, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">24&#x02009;880 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">15&#x02009;267 (2.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.6</td><td align="center" valign="top" rowspan="1" colspan="1">(2.9)</td><td align="center" valign="top" rowspan="1" colspan="1">(2.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">151&#x02009;649 (16.0)</td><td align="center" valign="top" rowspan="1" colspan="1">102&#x02009;551 (18.4)</td><td align="center" valign="top" rowspan="1" colspan="1">6.1</td><td align="center" valign="top" rowspan="1" colspan="1">(17.9)</td><td align="center" valign="top" rowspan="1" colspan="1">(17.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dyslipidemia, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">65&#x02009;057 (6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">45&#x02009;718 (8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">4.9</td><td align="center" valign="top" rowspan="1" colspan="1">(8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">(8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#x02010;hematological malignancy, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">74&#x02009;560 (7.9)</td><td align="center" valign="top" rowspan="1" colspan="1">38&#x02009;960 (7.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.5</td><td align="center" valign="top" rowspan="1" colspan="1">(7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">(7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hematological malignancy, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6422 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">6270 (1.1)</td><td align="center" valign="top" rowspan="1" colspan="1">4.7</td><td align="center" valign="top" rowspan="1" colspan="1">(1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">(1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dementia, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">161&#x02009;789 (17.1)</td><td align="center" valign="top" rowspan="1" colspan="1">71&#x02009;595 (12.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;12.1</td><td align="center" valign="top" rowspan="1" colspan="1">(13.9)</td><td align="center" valign="top" rowspan="1" colspan="1">(13.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" colspan="7" valign="top" rowspan="1">Treatment within 2&#x02009;days of admission day, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Oxygenation</td><td align="center" valign="top" rowspan="1" colspan="1">556&#x02009;927 (58.9)</td><td align="center" valign="top" rowspan="1" colspan="1">294&#x02009;768 (52.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;12.4</td><td align="center" valign="top" rowspan="1" colspan="1">(52.4)</td><td align="center" valign="top" rowspan="1" colspan="1">(52.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mechanical ventilation</td><td align="center" valign="top" rowspan="1" colspan="1">29&#x02009;699 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">15&#x02009;492 (2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">(2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">(2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Vasopressors</td><td align="center" valign="top" rowspan="1" colspan="1">22&#x02009;531 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">13&#x02009;236 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.1</td><td align="center" valign="top" rowspan="1" colspan="1">(2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">(2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Renal replacement therapy</td><td align="center" valign="top" rowspan="1" colspan="1">7341 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">9502 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td><td align="center" valign="top" rowspan="1" colspan="1">(1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">(1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Oral feeding</td><td align="center" valign="top" rowspan="1" colspan="1">557&#x02009;843 (59.0)</td><td align="center" valign="top" rowspan="1" colspan="1">418&#x02009;858 (75.0)</td><td align="center" valign="top" rowspan="1" colspan="1">34.4</td><td align="center" valign="top" rowspan="1" colspan="1">(72.3)</td><td align="center" valign="top" rowspan="1" colspan="1">(72.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Tube feeding</td><td align="center" valign="top" rowspan="1" colspan="1">17&#x02009;320 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">6689 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;5.2</td><td align="center" valign="top" rowspan="1" colspan="1">(1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">(1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Total parenteral nutrition</td><td align="center" valign="top" rowspan="1" colspan="1">7540 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">2516 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;4.4</td><td align="center" valign="top" rowspan="1" colspan="1">(0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">(0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Fibrates</td><td align="center" valign="top" rowspan="1" colspan="1">2131 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1923 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2.2</td><td align="center" valign="top" rowspan="1" colspan="1">(0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">(0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Somatostatin analogs</td><td align="center" valign="top" rowspan="1" colspan="1">38 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hormone replacement</td><td align="center" valign="top" rowspan="1" colspan="1">243 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">218 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">(0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Macrolide</td><td align="center" valign="top" rowspan="1" colspan="1">58&#x02009;964 (6.2)</td><td align="center" valign="top" rowspan="1" colspan="1">77&#x02009;398 (13.9)</td><td align="center" valign="top" rowspan="1" colspan="1">25.5</td><td align="center" valign="top" rowspan="1" colspan="1">(10.4)</td><td align="center" valign="top" rowspan="1" colspan="1">(10.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Fluoroquinolone</td><td align="center" valign="top" rowspan="1" colspan="1">24&#x02009;336 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">23&#x02009;893 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">9.4</td><td align="center" valign="top" rowspan="1" colspan="1">(3.7)</td><td align="center" valign="top" rowspan="1" colspan="1">(3.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Doxycycline</td><td align="center" valign="top" rowspan="1" colspan="1">13&#x02009;313 (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">14&#x02009;578 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td><td align="center" valign="top" rowspan="1" colspan="1">(2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">(2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Anti&#x02010;MRSA</td><td align="center" valign="top" rowspan="1" colspan="1">2334 (0.2)</td><td align="center" valign="top" rowspan="1" colspan="1">2663 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">3.8</td><td align="center" valign="top" rowspan="1" colspan="1">(0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">(0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Steroids</td><td align="center" valign="top" rowspan="1" colspan="1">45&#x02009;232 (4.8)</td><td align="center" valign="top" rowspan="1" colspan="1">35&#x02009;115 (6.3)</td><td align="center" valign="top" rowspan="1" colspan="1">6.6</td><td align="center" valign="top" rowspan="1" colspan="1">(5.5)</td><td align="center" valign="top" rowspan="1" colspan="1">(5.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Teaching hospital admission, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="top" rowspan="1" colspan="1">758&#x02009;495 (80.3)</td><td align="center" valign="top" rowspan="1" colspan="1">443&#x02009;436 (79.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">(77.8)</td><td align="center" valign="top" rowspan="1" colspan="1">(77.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0</td></tr></tbody></table><table-wrap-foot id="pds70162-ntgp-0002"><fn id="pds70162-note-0002"><p>
<italic toggle="yes">Note:</italic> The total number of etiologies does not add up to 100% as more than one cause can be assigned to a single patient.</p></fn><fn id="pds70162-note-0003"><p>Abbreviations: BMI, body mass index; GCS, Glasgow Coma Scale; HCU, high care unit; ICU, intensive care unit; MRSA, methicillin resistance in <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Staphylococcus aureus</italic>
</styled-content>; NTM, non&#x02010;tuberculosis mycobacterium; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><p>After applying propensity&#x02010;score overlap weighting, all baseline characteristics were well&#x02010;balanced (Table&#x000a0;<xref rid="pds70162-tbl-0001" ref-type="table">1</xref>). In the weighted population, the proportion of the composite outcome was higher in the ceftriaxone group than in the control group (0.22% vs. 0.18%; RD, 0.05%; 95% CI, 0.03%&#x02013;0.07%; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001) (Table&#x000a0;<xref rid="pds70162-tbl-0002" ref-type="table">2</xref>). The risk ratio was 1.27; the number needed to harm was 2079. The proportions of the following secondary outcomes were also higher in the ceftriaxone group: complications of cholecystitis or cholangitis during hospitalization and percutaneous or endoscopic drainage of the gallbladder or biliary tract (Table&#x000a0;<xref rid="pds70162-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="pds70162-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Comparison of outcomes between groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Control</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ceftriaxone</th><th align="center" valign="bottom" rowspan="1" colspan="1">Risk difference</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% confidence interval</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="6" valign="top" rowspan="1">Primary outcome, %</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Crude</td><td align="center" valign="top" rowspan="1" colspan="1">0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.00 to 0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.189</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Propensity score overlap weighting</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.22</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 to 0.07</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">Secondary outcome, %</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" valign="top" rowspan="1">Complication of cholecystitis or cholangitis during hospitalization</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Crude</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.00 to 0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.205</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Propensity score overlap weighting</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 to 0.06</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" valign="top" rowspan="1">Percutaneous or endoscopic drainage on the gallbladder or biliary tract</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Crude</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.00 to 0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.174</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Propensity score overlap weighting</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.07</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 to 0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" style="padding-left:10%" colspan="6" valign="top" rowspan="1">Surgical interventions on the gallbladder or biliary tract</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Crude</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.00 to 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.994</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Propensity score overlap weighting</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.00 to 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.899</td></tr></tbody></table><table-wrap-foot id="pds70162-ntgp-0003"><fn id="pds70162-note-0004"><p>
<italic toggle="yes">Note:</italic> Primary outcome was defined as a composite outcome of the complications of cholecystitis or cholangitis during hospitalization, percutaneous or endoscopic drainage on the gallbladder or biliary tract, and surgical interventions on the gallbladder or biliary tract.</p></fn></table-wrap-foot></table-wrap><p>Table&#x000a0;<xref rid="pds70162-tbl-0003" ref-type="table">3</xref> shows the results of the sensitivity analyses. Patients who received high&#x02010;dose ceftriaxone (&#x02265;&#x02009;2&#x02009;g/day) had a higher proportion of the primary outcome compared to those who received ampicillin&#x02010;sulbactam or cefotaxime (0.22% vs. 0.18%; RD, 0.04%; 95% CI, 0.02%&#x02013;0.06%; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). When comparing ceftriaxone to piperacillin&#x02010;tazobactam, the primary outcome was consistent with the main analysis (0.25% vs. 0.19%; RD, 0.05%; 95% CI, 0.02%&#x02013;0.08%; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). In the comparison between ceftriaxone and cefotaxime, there was no significant difference in the primary outcome (0.18% vs. 0.15%; RD, 0.03%; 95% CI, &#x02212;0.04% to 0.10%; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.416). However, percutaneous or endoscopic drainage of the gallbladder or biliary tract was significantly more frequent in the ceftriaxone group (0.05% vs. 0.01%; RD, 0.04%; 95% CI, 0.02%&#x02013;0.07%; <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001). The results of the sensitivity analysis including 30&#x02010;day readmissions for biliary infections were consistent with those of the main analysis (Table&#x000a0;<xref rid="pds70162-supitem-0001" ref-type="supplementary-material">S2</xref>).</p><table-wrap position="float" id="pds70162-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Sensitivity analyses of outcomes between propensity score weighted groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Risk difference</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% confidence interval</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="4" valign="top" rowspan="1">Ceftriaxone &#x02265;&#x02009;2&#x02009;g/day (<italic toggle="yes">n</italic>&#x02009;=&#x02009;361&#x02009;737) vs. ampicillin&#x02010;sulbactam or cefotaxime (<italic toggle="yes">n</italic>&#x02009;=&#x02009;945&#x02009;160)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary outcome, %</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 to 0.06</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" valign="top" rowspan="1">Secondary outcomes, %</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Complication of cholecystitis or cholangitis during hospitalization</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 to 0.06</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Percutaneous or endoscopic drainage on the gallbladder or biliary tract</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.00 to 0.03</td><td align="center" valign="top" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Surgical interventions on the gallbladder or biliary tract</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.01 to 0.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.682</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Ceftriaxone (<italic toggle="yes">n</italic>&#x02009;=&#x02009;573&#x02009;867) vs. piperacillin&#x02010;tazobactam (<italic toggle="yes">n</italic>&#x02009;=&#x02009;318&#x02009;510)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary outcome, %</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 to 0.08</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" valign="top" rowspan="1">Secondary outcomes, %</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Complication of cholecystitis or cholangitis during hospitalization</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 to 0.08</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Percutaneous or endoscopic drainage on the gallbladder or biliary tract</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.01 to 0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.360</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Surgical interventions on the gallbladder or biliary tract</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.00 to 0.01</td><td align="center" valign="top" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Ceftriaxone (<italic toggle="yes">n</italic>&#x02009;=&#x02009;558&#x02009;725) vs. cefotaxime (<italic toggle="yes">n</italic>&#x02009;=&#x02009;16&#x02009;303)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Primary outcome, %</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.04 to 0.10</td><td align="center" valign="top" rowspan="1" colspan="1">0.416</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" valign="top" rowspan="1">Secondary outcomes, %</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Complication of cholecystitis or cholangitis during hospitalization</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.06 to 0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.762</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Percutaneous or endoscopic drainage on the gallbladder or biliary tract</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td><td align="center" valign="top" rowspan="1" colspan="1">0.02 to 0.07</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Surgical interventions on the gallbladder or biliary tract</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.02 to 0.02</td><td align="center" valign="top" rowspan="1" colspan="1">0.952</td></tr></tbody></table><table-wrap-foot id="pds70162-ntgp-0004"><fn id="pds70162-note-0005"><p>
<italic toggle="yes">Note:</italic> Primary outcome was defined as a composite outcome of the complications of cholecystitis or cholangitis during hospitalization, percutaneous or endoscopic drainage on the gallbladder or biliary tract, and surgical interventions on the gallbladder or biliary tract.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="pds70162-sec-0019"><label>4</label><title>Discussion</title><p>In this retrospective study, we evaluated the association between ceftriaxone use and biliary infection in patients with pneumonia. Our findings revealed that the use of ceftriaxone was associated with a slight increase in the risk of biliary infection in these patients.</p><p>A major strength of the present study is the use of a large&#x02010;scale nationwide inpatient database. Previous studies investigating the association between ceftriaxone and biliary infections have been primarily limited to case reports. To date, no comprehensive analyses have been conducted to evaluate the clinical significance of ceftriaxone&#x02010;calcium precipitation [<xref rid="pds70162-bib-0011" ref-type="bibr">11</xref>, <xref rid="pds70162-bib-0012" ref-type="bibr">12</xref>, <xref rid="pds70162-bib-0013" ref-type="bibr">13</xref>]. In contrast, our study aimed to address this critical gap by assessing the association between ceftriaxone use and biliary infections among patients with pneumonia using a large nationwide database. To the best of our knowledge, this study is the first large&#x02010;scale comprehensive study to investigate the association and provides valuable epidemiological evidence on the potential risk of biliary complications with ceftriaxone use.</p><p>The exact pathogenic mechanism of pseudolithiasis remains unclear. It is hypothesized that ceftriaxone&#x02010;calcium precipitation in the bile leads to the formation of pseudolithiasis [<xref rid="pds70162-bib-0004" ref-type="bibr">4</xref>]. Other studies suggest that ceftriaxone may reduce gallbladder contractility or that genetic polymorphisms in the uridine 5&#x02010;diphosphate&#x02010;glucuronosyltransferase 1A1 gene may contribute to stone formation [<xref rid="pds70162-bib-0026" ref-type="bibr">26</xref>, <xref rid="pds70162-bib-0027" ref-type="bibr">27</xref>]. A previous double&#x02010;blind, placebo&#x02010;controlled study found that 21.4% of adults developed pseudolithiasis after receiving intravenous ceftriaxone at 2&#x02009;g/day for 14&#x02009;days [<xref rid="pds70162-bib-0004" ref-type="bibr">4</xref>]. Additionally, a large&#x02010;scale retrospective study reported that pseudolithiasis developed in 17% (89/523) of adult patients who received a total ceftriaxone dose of 9.1&#x02009;g (standard deviation, 12.4&#x02009;g) over a median treatment duration of 3&#x02009;days (interquartile range, 1&#x02013;66&#x02009;days) [<xref rid="pds70162-bib-0025" ref-type="bibr">25</xref>]. Since pseudolithiasis typically resolves spontaneously within 9&#x02013;26&#x02009;days after discontinuation of ceftriaxone, it remains uncertain whether ceftriaxone&#x02010;induced pseudolithiasis significantly increases the risk of biliary diseases in patients receiving standard treatment for pneumonia [<xref rid="pds70162-bib-0004" ref-type="bibr">4</xref>].</p><p>In our study, the mean initial dose of ceftriaxone was 1.7&#x02009;g/day (standard deviation, 0.7&#x02009;g), and the mean duration of administration was 7.1&#x02009;days (standard deviation, 3.8&#x02009;days). Although ceftriaxone use was associated with a slight increase in the risk of biliary infections, this risk should be weighed against the benefits of ceftriaxone in treating pneumonia, including its broad antimicrobial spectrum, convenience of once&#x02010;daily dosing, and availability. Considering the relatively small increase in risk, it may not be necessary to focus heavily on biliary complications when using ceftriaxone in standard clinical practice for pneumonia management [<xref rid="pds70162-bib-0028" ref-type="bibr">28</xref>].</p><p>This study has some limitations. First, this was a retrospective analysis based on a nationwide database. Due to the nature of the database, which is primarily used for reimbursement purposes, detailed clinical information, such as laboratory test results and imaging findings, was not available. Although complications and surgical procedures are generally expected to be recorded with high specificity due to using reimbursement claims, the accuracy of diagnostic coding for specific conditions such as cholecystitis and cholangitis may not be fully confirmed. Furthermore, we could not rule out the risk of misclassification bias regarding whether the included procedures, such as drainage and surgical interventions in the gallbladder or biliary tract, could have been performed for other indications. Additionally, although we adjusted for several measured confounders, the potential impact of unmeasured confounders could not be excluded. These limitations may have affected the internal validity of our findings. Second, we excluded patients with pre&#x02010;existing gallbladder or biliary tract disease. As a result, the impact of ceftriaxone use on the risk of biliary infections in patients with such coexisting conditions remains unclear. Third, this study was based on an inpatient database, and outcomes that occurred after discharge could not be fully assessed. Ceftriaxone&#x02010;induced pseudolithiasis is generally expected to resolve spontaneously after ceftriaxone discontinuation. We also performed a sensitivity analysis that included patients who were readmitted for biliary infections within 30&#x02009;days after discharge and confirmed the robustness of our findings. However, it remains possible that not all outcomes might have been fully assessed, which might have led to an underestimation of the true incidence of biliary complications.</p></sec><sec sec-type="conclusions" id="pds70162-sec-0020"><label>5</label><title>Conclusion</title><p>This study found that ceftriaxone use in patients with pneumonia was associated with a slight increase in the risk of biliary infections. Although this risk is statistically significant, it is relatively small in magnitude. Clinicians should be aware of this risk, but given the broad benefits of ceftriaxone in treating pneumonia, it may not warrant significant changes in clinical practice for most patients.</p><sec id="pds70162-sec-0021"><label>5.1</label><title>Plain Language Summary</title><p>Ceftriaxone is a common antibiotic used to treat infections including pneumonia. However, it can sometimes cause a condition called pseudolithiasis, where calcium builds up and forms stone&#x02010;like deposits in the gallbladder or bile ducts. This may increase the risk of biliary infections, such as cholecystitis (inflammation of the gallbladder) and cholangitis (inflammation of the bile ducts). In this study, we analyzed a large national database of hospitalized pneumonia patients in Japan from 2010 to 2022. We compared patients who received ceftriaxone with those treated with other antibiotics like ampicillin&#x02010;sulbactam or cefotaxime. Our analysis found that patients treated with ceftriaxone had a slightly higher risk of developing biliary infections or needing drainage procedures during their hospital stay (0.22% vs. 0.18%). Although this difference was statistically significant, the overall risk was very low. This information can help healthcare providers make more informed decisions when prescribing antibiotics, especially for patients who may be more susceptible to biliary problems.</p></sec></sec><sec id="pds70162-sec-0024"><title>Author Contributions</title><p>J.T. conceived, designed, analyzed, and coordinated this study. J.T. and S.A. wrote the first draft of the manuscript. H.Y. contributed to the data interpretation and assisted with the manuscript preparation. S.A., H.M., K.F., and H.Y. critically reviewed the manuscript. H.Y. critically appraised the manuscript. All the authors have read and approved the final version of the manuscript.</p></sec><sec sec-type="COI-statement" id="pds70162-sec-0022"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pds70162-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Table&#x000a0;S1.</bold> ICD&#x02010;10 codes used to define each comorbidity.</p><p>
<bold>Table&#x000a0;S2.</bold> Sensitivity analysis including patients who were readmitted for biliary infections within 30&#x02009;days after discharge.</p></caption><media xlink:href="PDS-34-e70162-s001.docx"/></supplementary-material></sec></body><back><ack id="pds70162-sec-0023"><title>Acknowledgments</title><p>This work was supported by grants from the Ministry of Health, Labor and Welfare, Japan (23AA2003 and 24AA2006). The sponsors had no role in the study design, data collection, analysis, or writing of the manuscript.</p></ack><sec sec-type="data-availability" id="pds70162-sec-0026"><title>Data Availability Statement</title><p>The datasets used in this study are not available.</p></sec><ref-list content-type="cited-references" id="pds70162-bibl-0001"><title>References</title><ref id="pds70162-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="pds70162-cit-0001">
<string-name>
<given-names>D. M.</given-names>
<surname>Richards</surname>
</string-name>, <string-name>
<given-names>R. C.</given-names>
<surname>Heel</surname>
</string-name>, <string-name>
<given-names>R. N.</given-names>
<surname>Brogden</surname>
</string-name>, <string-name>
<given-names>T. M.</given-names>
<surname>Speight</surname>
</string-name>, and <string-name>
<given-names>G. S.</given-names>
<surname>Avery</surname>
</string-name>, &#x0201c;<article-title>Ceftriaxone. A Review of Its Antibacterial Activity, Pharmacological Properties and Therapeutic Use</article-title>,&#x0201d; <source>Drugs</source>
<volume>27</volume>, no. <issue>6</issue> (<year>1984</year>): <fpage>469</fpage>&#x02013;<lpage>527</lpage>.<pub-id pub-id-type="pmid">6329638</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="pds70162-cit-0002">
<string-name>
<given-names>H. M.</given-names>
<surname>Lamb</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Ormrod</surname>
</string-name>, <string-name>
<given-names>L. J.</given-names>
<surname>Scott</surname>
</string-name>, and <string-name>
<given-names>D. P.</given-names>
<surname>Figgitt</surname>
</string-name>, &#x0201c;<article-title>Ceftriaxone: An Update of Its Use in the Management of Community&#x02010;Acquired and Nosocomial Infections</article-title>,&#x0201d; <source>Drugs</source>
<volume>62</volume>, no. <issue>7</issue> (<year>2002</year>): <fpage>1041</fpage>&#x02013;<lpage>1089</lpage>.<pub-id pub-id-type="pmid">11985490</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="pds70162-cit-0003">
<string-name>
<given-names>J. M.</given-names>
<surname>Brogard</surname>
</string-name>, <string-name>
<given-names>J. F.</given-names>
<surname>Blickle</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Jehl</surname>
</string-name>, <string-name>
<given-names>J. P.</given-names>
<surname>Arnaud</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Paris&#x02010;Bockel</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Monteil</surname>
</string-name>, &#x0201c;<article-title>High Biliary Elimination of Ceftriaxone in Man</article-title>,&#x0201d; <source>International Journal of Clinical Pharmacology, Therapy, and Toxicology</source>
<volume>26</volume>, no. <issue>4</issue> (<year>1988</year>): <fpage>167</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">3403093</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="pds70162-cit-0004">
<string-name>
<given-names>K. L.</given-names>
<surname>Heim&#x02010;Duthoy</surname>
</string-name>, <string-name>
<given-names>E. M.</given-names>
<surname>Caperton</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Pollock</surname>
</string-name>, <string-name>
<given-names>G. R.</given-names>
<surname>Matzke</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Enthoven</surname>
</string-name>, and <string-name>
<given-names>P. K.</given-names>
<surname>Peterson</surname>
</string-name>, &#x0201c;<article-title>Apparent Biliary Pseudolithiasis During Ceftriaxone Therapy</article-title>,&#x0201d; <source>Antimicrobial Agents and Chemotherapy</source>
<volume>34</volume>, no. <issue>6</issue> (<year>1990</year>): <fpage>1146</fpage>&#x02013;<lpage>1149</lpage>.<pub-id pub-id-type="pmid">2203305</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="pds70162-cit-0005">
<string-name>
<given-names>A.</given-names>
<surname>Bartkowska&#x02010;&#x0015a;niatkowska</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Jo&#x00144;czyk&#x02010;Potoczna</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Zieli&#x00144;ska</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Rosada&#x02010;Kurasi&#x00144;ska</surname>
</string-name>, &#x0201c;<article-title>Adverse Reaction to Ceftriaxone in a 28&#x02010;Day&#x02010;Old Infant Undergoing Urgent Craniotomy due to Epidural Hematoma: Review of Neonatal Biliary Pseudolithiasis</article-title>,&#x0201d; <source>Therapeutics and Clinical Risk Management</source>
<volume>11</volume> (<year>2015</year>): <fpage>1035</fpage>&#x02013;<lpage>1041</lpage>.<pub-id pub-id-type="pmid">26170682</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="pds70162-cit-0006">
<string-name>
<given-names>A.</given-names>
<surname>Soysal</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Era&#x0015f;ov</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Akpinar</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Bakir</surname>
</string-name>, &#x0201c;<article-title>Biliary Precipitation During Ceftriaxone Therapy: Frequency and Risk Factors</article-title>,&#x0201d; <source>Turkish Journal of Pediatrics</source>
<volume>49</volume>, no. <issue>4</issue> (<year>2007</year>): <fpage>404</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">18246742</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="pds70162-cit-0007">
<string-name>
<given-names>A.</given-names>
<surname>Palanduz</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Yal&#x000e7;in</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Tongu&#x000e7;</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Sonographic Assessment of Ceftriaxone&#x02010;Associated Biliary Pseudolithiasis in Children</article-title>,&#x0201d; <source>Journal of Clinical Ultrasound</source>
<volume>28</volume>, no. <issue>4</issue> (<year>2000</year>): <fpage>166</fpage>&#x02013;<lpage>168</lpage>, <pub-id pub-id-type="doi">10.1002/(sici)1097-0096(200005)28:4&#x0003c;166::aid-jcu2&#x0003e;3.0.co;2-g</pub-id>.<pub-id pub-id-type="pmid">10751736</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="pds70162-cit-0008">
<string-name>
<given-names>G.</given-names>
<surname>Azarkar</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Birjand</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Ehsanbakhsh</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Bijari</surname>
</string-name>, <string-name>
<given-names>M. R.</given-names>
<surname>Abedini</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Ziaee</surname>
</string-name>, &#x0201c;<article-title>Ceftriaxone&#x02010;Associated Nephrolithiasis and Gallstone in Adults</article-title>,&#x0201d; <source>Drug, Healthcare and Patient Safety</source>
<volume>10</volume> (<year>2018</year>): <fpage>103</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">30588126</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="pds70162-cit-0009">
<string-name>
<given-names>K.</given-names>
<surname>Hotta</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Hashimura</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Takatsuka</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Ceftriaxone&#x02010;Associated Pseudolithiasis in Elderly People: Frequency and Risk Factors</article-title>,&#x0201d; <source>Internal Medicine</source>
<volume>60</volume>, no. <issue>24</issue> (<year>2021</year>): <fpage>3857</fpage>&#x02013;<lpage>3864</lpage>.<pub-id pub-id-type="pmid">34911872</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="pds70162-cit-0010">
<string-name>
<given-names>R.</given-names>
<surname>Yoshida</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Yoshizako</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Katsube</surname>
</string-name>, and <string-name>
<given-names>H.</given-names>
<surname>Kitagaki</surname>
</string-name>, &#x0201c;<article-title>Computed Tomography Findings of Ceftriaxone&#x02010;Associated Biliary Pseudocholelithiasis in Adults</article-title>,&#x0201d; <source>Japanese Journal of Radiology</source>
<volume>37</volume>, no. <issue>12</issue> (<year>2019</year>): <fpage>826</fpage>&#x02013;<lpage>831</lpage>.<pub-id pub-id-type="pmid">31654330</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="pds70162-cit-0011">
<string-name>
<given-names>F. M.</given-names>
<surname>Gomes</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Costeira</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Leite</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Silva</surname>
</string-name>, &#x0201c;<article-title>Ceftriaxone&#x02010;Induced Acute Cholecystitis</article-title>,&#x0201d; <source>Journal of Ultrasound in Medicine</source>
<volume>29</volume>, no. <issue>4</issue> (<year>2021</year>): <fpage>288</fpage>&#x02013;<lpage>290</lpage>.</mixed-citation></ref><ref id="pds70162-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="pds70162-cit-0012">
<string-name>
<given-names>T.</given-names>
<surname>Shigemori</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Imoto</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Inoue</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Acute Necrotizing Calculous Cholecystitis After Treatment With Ceftriaxone in an Elderly Patient: A Case Report</article-title>,&#x0201d; <source>Surgical Case Reports</source>
<volume>8</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>97</fpage>.<pub-id pub-id-type="pmid">35581487</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="pds70162-cit-0013">
<string-name>
<given-names>C. D.</given-names>
<surname>Becker</surname>
</string-name> and <string-name>
<given-names>R. A.</given-names>
<surname>Fischer</surname>
</string-name>, &#x0201c;<article-title>Acute Cholecystitis Caused by Ceftriaxone Stones in an Adult</article-title>,&#x0201d; <source>Case Reports in Medicine</source>
<volume>2009</volume> (<year>2009</year>): <elocation-id>132452</elocation-id>.<pub-id pub-id-type="pmid">19707473</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="pds70162-cit-0014">
<string-name>
<given-names>L.</given-names>
<surname>Zeng</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Jiang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Safety of Ceftriaxone in Paediatrics: A Systematic Review</article-title>,&#x0201d; <source>Archives of Disease in Childhood</source>
<volume>105</volume>, no. <issue>10</issue> (<year>2020</year>): <fpage>981</fpage>&#x02013;<lpage>985</lpage>.<pub-id pub-id-type="pmid">32144089</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="pds70162-cit-0015">
<string-name>
<given-names>C. L.</given-names>
<surname>Bickford</surname>
</string-name> and <string-name>
<given-names>A. P.</given-names>
<surname>Spencer</surname>
</string-name>, &#x0201c;<article-title>Biliary Sludge and Hyperbilirubinemia Associated With Ceftriaxone in an Adult: Case Report and Review of the Literature</article-title>,&#x0201d; <source>Pharmacotherapy</source>
<volume>25</volume>, no. <issue>10</issue> (<year>2005</year>): <fpage>1389</fpage>&#x02013;<lpage>1395</lpage>.<pub-id pub-id-type="pmid">16185184</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="pds70162-cit-0016">
<string-name>
<given-names>H.</given-names>
<surname>Yasunaga</surname>
</string-name>, &#x0201c;<article-title>Chapter II. The Diagnosis Procedure Combination Database</article-title>,&#x0201d; <source>Annals of Clinical Epidemiology</source>
<volume>1</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>76</fpage>&#x02013;<lpage>79</lpage>.</mixed-citation></ref><ref id="pds70162-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="pds70162-cit-0017">
<string-name>
<given-names>H.</given-names>
<surname>Yasunaga</surname>
</string-name>, &#x0201c;<article-title>Updated Information on the Diagnosis Procedure Combination Data</article-title>,&#x0201d; <source>Annals of Clinical Epidemiology</source>
<volume>6</volume>, no. <issue>4</issue> (<year>2024</year>): <fpage>106</fpage>&#x02013;<lpage>110</lpage>, <pub-id pub-id-type="doi">10.37737/ace.24015</pub-id>.<pub-id pub-id-type="pmid">39726797</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="pds70162-cit-0018">
<string-name>
<given-names>F. I.</given-names>
<surname>Mahoney</surname>
</string-name> and <string-name>
<given-names>D. W.</given-names>
<surname>Barthel</surname>
</string-name>, &#x0201c;<article-title>Functional Evaluation: The Barthel Index</article-title>,&#x0201d; <source>Maryland State Medical Journal</source>
<volume>14</volume> (<year>1965</year>): <fpage>61</fpage>&#x02013;<lpage>65</lpage>.</mixed-citation></ref><ref id="pds70162-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="pds70162-cit-0019">
<string-name>
<given-names>M.</given-names>
<surname>Nakajima</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Okada</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Sonoo</surname>
</string-name>, and <string-name>
<given-names>T.</given-names>
<surname>Goto</surname>
</string-name>, &#x0201c;<article-title>Development and Validation of a Novel Method for Converting the Japan Coma Scale to Glasgow Coma Scale</article-title>,&#x0201d; <source>Journal of Epidemiology</source>
<volume>33</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>531</fpage>&#x02013;<lpage>535</lpage>.<pub-id pub-id-type="pmid">35851565</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="pds70162-cit-0020">
<string-name>
<given-names>K.</given-names>
<surname>Shigematsu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Nakano</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Watanabe</surname>
</string-name>, &#x0201c;<article-title>The Eye Response Test Alone Is Sufficient to Predict Stroke Outcome&#x02014;Reintroduction of Japan Coma Scale: A Cohort Study</article-title>,&#x0201d; <source>BMJ Open</source>
<volume>3</volume>, no. <issue>4</issue> (<year>2013</year>): <elocation-id>e002736</elocation-id>, <pub-id pub-id-type="doi">10.1136/bmjopen-2013-002736</pub-id>.</mixed-citation></ref><ref id="pds70162-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="pds70162-cit-0021">
<string-name>
<given-names>R. J.</given-names>
<surname>Desai</surname>
</string-name> and <string-name>
<given-names>J. M.</given-names>
<surname>Franklin</surname>
</string-name>, &#x0201c;<article-title>Alternative Approaches for Confounding Adjustment in Observational Studies Using Weighting Based on the Propensity Score: A Primer for Practitioners</article-title>,&#x0201d; <source>BMJ</source>
<volume>367</volume> (<year>2019</year>): <elocation-id>l5657</elocation-id>.<pub-id pub-id-type="pmid">31645336</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="pds70162-cit-0022">
<string-name>
<given-names>L. E.</given-names>
<surname>Thomas</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Li</surname>
</string-name>, and <string-name>
<given-names>M. J.</given-names>
<surname>Pencina</surname>
</string-name>, &#x0201c;<article-title>Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial</article-title>,&#x0201d; <source>JAMA</source>
<volume>323</volume>, no. <issue>23</issue> (<year>2020</year>): <fpage>2417</fpage>&#x02013;<lpage>2418</lpage>.<pub-id pub-id-type="pmid">32369102</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="pds70162-cit-0023">
<string-name>
<given-names>P. C.</given-names>
<surname>Austin</surname>
</string-name>, &#x0201c;<article-title>Balance Diagnostics for Comparing the Distribution of Baseline Covariates Between Treatment Groups in Propensity&#x02010;Score Matched Samples</article-title>,&#x0201d; <source>Statistics in Medicine</source>
<volume>28</volume>, no. <issue>25</issue> (<year>2009</year>): <fpage>3083</fpage>&#x02013;<lpage>3107</lpage>.<pub-id pub-id-type="pmid">19757444</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="pds70162-cit-0024">
<string-name>
<given-names>P. C.</given-names>
<surname>Austin</surname>
</string-name> and <string-name>
<given-names>E. A.</given-names>
<surname>Stuart</surname>
</string-name>, &#x0201c;<article-title>Moving Towards Best Practice When Using Inverse Probability of Treatment Weighting (IPTW) Using the Propensity Score to Estimate Causal Treatment Effects in Observational Studies</article-title>,&#x0201d; <source>Statistics in Medicine</source>
<volume>34</volume>, no. <issue>28</issue> (<year>2015</year>): <fpage>3661</fpage>&#x02013;<lpage>3679</lpage>.<pub-id pub-id-type="pmid">26238958</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="pds70162-cit-0025">
<string-name>
<given-names>A.</given-names>
<surname>Matsumi</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Tomoda</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Terasawa</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Risk Factors for Ceftriaxone&#x02010;Associated Pseudolithiasis in Adults</article-title>,&#x0201d; <source>Digestion</source>
<volume>104</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>313</fpage>&#x02013;<lpage>319</lpage>.<pub-id pub-id-type="pmid">36907172</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="pds70162-cit-0026">
<string-name>
<given-names>M.</given-names>
<surname>Arpacik</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Ceran</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Kaya</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Karadas</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Sarac</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Koyluo&#x0011f;lu</surname>
</string-name>, &#x0201c;<article-title>Effects of Ceftriaxone Sodium on In&#x000a0;Vitro Gallbladder Contractility in Guinea Pigs</article-title>,&#x0201d; <source>Journal of Surgical Research</source>
<volume>122</volume>, no. <issue>2</issue> (<year>2004</year>): <fpage>157</fpage>&#x02013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">15555612</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="pds70162-cit-0027">
<string-name>
<given-names>A.</given-names>
<surname>Fretzayas</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Liapi</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Papadopoulou</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Nicolaidou</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Stamoulakatou</surname>
</string-name>, &#x0201c;<article-title>Is Ceftriaxone&#x02010;Induced Biliary Pseudolithiasis Influenced by UDP&#x02010;Glucuronosyltransferase 1A1 Gene Polymorphisms?</article-title>,&#x0201d; <source>Case Reports in Medicine</source>
<volume>2011</volume> (<year>2011</year>): <elocation-id>730250</elocation-id>.<pub-id pub-id-type="pmid">22110515</pub-id>
</mixed-citation></ref><ref id="pds70162-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="pds70162-cit-0028">
<string-name>
<given-names>J. P.</given-names>
<surname>Metlay</surname>
</string-name>, <string-name>
<given-names>G. W.</given-names>
<surname>Waterer</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Long</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Diagnosis and Treatment of Adults With Community&#x02010;Acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America</article-title>,&#x0201d; <source>American Journal of Respiratory and Critical Care Medicine</source>
<volume>200</volume>, no. <issue>7</issue> (<year>2019</year>): <fpage>e45</fpage>&#x02013;<lpage>e67</lpage>.<pub-id pub-id-type="pmid">31573350</pub-id>
</mixed-citation></ref></ref-list></back></article>